Investor Area

Home / Investor Area / News / CUV103 Singaporean Phase II vitiligo study results

CUV103 Singaporean Phase II vitiligo study results

19 December 2018

 

Summary

• n=21, patients of Asian ethnicity, darker skin complexion
• Pooled analysis of data collected on all patients who received SCENESSE® with NB-UVB (n=18)
• Six doses of SCENESSE® subcutaneously administered monthly in combination with NB-UVB twice a week
• Repigmentation therapy with SCENESSE® in combination with NB-UVB effective and safety profile maintained:
     – Statistically significant increase in pigmentation on areas of vitiligo for total body, areas of head and neck
       (VASI, p<0.001 at Day 196), as well hands, upper extremities, trunk and lower extremities (VASI, p<0.05
        at Day 196), with exception of the feet
     – Maintenance of pigmentation observed at Day 280, three months after the end of the treatment
     – Combination therapy of SCENESSE® with NB-UVB well tolerated

 

Download PDF to read more